Orthovita plans European launch of injectable synthetic bone product early next year
This article was originally published in Clinica
Executive Summary
Biomaterials company Orthovita is undertaking trials in Europe of an injectable synthetic bone for treating compression of the spine, a condition that affects 700,000 patients per year worldwide and is caused by osteoporosis, trauma and bone cancer.